[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stable-chronic-hypercapnic-respiratory-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stable-chronic-hypercapnic-respiratory-failure":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100583167","home-high-flow-nasal-cannula-vs-noninvasive-ventilation-for-stable-chronic-respiratory-failure-100583167",false,"NCT06872801","Home High-Flow Nasal Cannula vs. Noninvasive Ventilation for Stable Chronic Respiratory Failure","Comparison of the Effects of Home High-Flow Nasal Cannula Therapy and Noninvasive Ventilation in Patients With Stable Chronic Hypercapnic Respiratory Failure","Inclusion Criteria:\n\n* Adult aged 40 years or older\n* Diagnosed with COPD\n* Arterial blood gas test, pCO2 \\> 45 mmHg at stable status\n* A person who can read or write in Korean\n* Written informed consent to participate in this study\n\nExclusion Criteria:\n\n* A person who disagrees with the content of a informed consent\n* Those who have difficulty wearing NIV or HFNC\n* Cognitive impairment or apsychiatric disorder\n* Hypoxic or hypercapnic exacerbation within the previous four weeks","ALL","40 Years",{"count":19,"type":20},38,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to compare the effects of home high-flow nasal cannula (HFNC) therapy and noninvasive ventilation (NIV) in patients with stable chronic hypercapnic respiratory failure. The main questions it aims to answer are:\n\n* Does HFNC or NIV reduce blood carbon dioxide levels more effectively?\n* How well do patients tolerate and adhere to each therapy?\n* Are there differences in oxygen saturation, respiratory rate, and quality of life between the two treatments?\n\nParticipants Will:\n\n* Use either HFNC (myAirvo2®) or NIV (Trilogy Evo®) every night for at least 4 hours over a 6-week period.\n* Visit the hospital for checkups and arterial blood gas tests at the end of each 6-week period.\n* Switch to the alternate device after six weeks as part of the crossover study design.\n* Have their device usage recorded and analyzed.",[26],"Stable Chronic Hypercapnic Respiratory Failure",[28,29,30,31,32],"Chronic Hypercapnic Respiratory Failure","Noninvasive Ventilation","High-Flow Nasal Cannula","Randomized Controlled Trial","Crossover Design","NOT_YET_RECRUITING","2025-03-10",{"date":36,"type":37},"2025-03-12","ACTUAL",{"date":39,"type":20},"2025-03",{"date":41,"type":20},"2026-06",{"name":43,"class":44},"Wonju Severance Christian Hospital","OTHER"]